COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by a quantitative and sensitive immunoassay

Patients and clinical samples

This study was reviewed and approved by the Medical Ethical Committee of the First Affiliated Hospital of USTC (approval number: 2020-XG(H)-014) and the First Affiliated Hospital of Anhui Medical University (approval number: Quick-PJ 2020-04-16). Patient information is listed in supplementary table 1.

Confirmed COVID-19 cases and clinical classifications were defined according to the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China. This study enrolls a total of 87 cases of confirmed COVID-19 patients, who were admitted to the First Affiliated Hospital of USTC Hospital or the First Affiliated Hospital of Anhui Medical University between Jan 26 and Mar 5, 2020. Their blood samples were collected during routine clinical testing. All enrolled cases were confirmed to be infected with SARS-CoV-2 by use of a standard RT-qPCR assay on throat swab samples from the respiratory tract. For all of the enrolled patients, the date of illness onset, clinical classifications of severity, RNA testing results during the hospitalization period, and the personal demographic information, were obtained from the clinical records.

Among them, five patients were admitted to the ICU, one was died of cerebral hemorrhage after stroke. Twenty-two patients had severe COVID-19, and all of whom required oxygen supplementation. Fifty-six patients had moderate and nine patients had mild COVID-19. The median age of patients was 48 years (range 21–91), and the average age of patients was 47.4 years. Thirty seven (42·5%) patients had underline illnesses; the most common one was hypertension in eighteen patients (20·7%). A total 216 serum samples were taken from the 87 COVID-19 patients.

Negative controls and potentially interfering non-COVID-19 patient serum samples were collected in order to evaluate the reliability of the kits. This cohort contains 330 sera from obviously healthy people, fifteen sera from once suspected cases (RT-qPCR negative but had typical manifestation of pneumonia) and 138 sera from other patients with different underlying diseases. All sera were stored at -20°C.

Molecular cloning, protein expression and purification

The viral nucleocapsid protein (NP) was expressed and purified from E. coli. Briefly, special treatment during the addition of high salt in lysis buffer and a hydrophobic interaction column was used to completely remove non-specific nucleic acid contamination. Our final protein was homogeneous and free of nucleic acid contamination as revealed by gel filtration and UV-Vis spectrum.

To make recombinant SARS-CoV-2 RBD in mammalian cells, an IFNA1 signal peptide DNA sequence, and DNA sequences encoding receptor binding region of spike protein and a human IgG1 Fc were fused together and cloned into pTT5 vector. The constructed expression vector was used to transiently transfect human HEK293F cells by polyethylenimine. After three days of expression, fusion protein was purified from cell supernatant using a Protein A column.

Diagnostic kit preparation and testing

Briefly, the purified NP or RBD viral antigens were coated to magnetic particles to catch SARS-CoV-2 specific IgA, IgM, and IgG in patient sera. Then a second antibody that recognizes IgA, IgM, or IgG is conjugated with acridinium (which can react with substrates to generate a strong chemiluminescence) was added for detection of IgA, IgM, and IgG, respectively. The detected chemiluminescent signal over background signal was calculated as relative light units (RLU). Serum samples were collected by centrifugation of whole blood in test tubes at room temperature for 15 min. Prior to testing, a denaturant solution was added to each serum to a final concentration of 1% TNBP, 1% Triton X-100. After adequate mixing by inverting, the samples were incubated at 30°C for 4 hours to completely denature any potential viruses. Such solvent/detergent (1% TNBP + 1% Triton X-100) treatment is recommended by WHO guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products (https://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf) ²⁵. Virus deactivated serum samples were then diluted 40 times with dilution buffer and subjected to testing at room temperature. Then RLU was measured using a fully automatic chemical luminescent immunoanalyzer, Kaeser 1000 (Kangrun Biotech, Guangzhou, China).

SARS-CoV-2 RBD-specific IgA, IgM, and IgG antibodies were purified from a serum pool of recovering patients (a manuscript in preparation) to be used as standards. The concentrations were determined using Bradford method (using bovine serum albumin protein as a standard). These antibodies were used to make a standard curve for each antibody detection kits to quantify the absolute antibody amounts in serum.

Statistical analysis

Based on the clinical RT-qPCR diagnosis results of SARS-CoV-2 infection, receiver operating characteristic (ROC) analysis was conducted using MedCalc software to determine the optimal cut-off value (criterion) and evaluate the diagnostic value of NP-or RBD-specific IgA, IgM, and IgG kits. The specificity and sensitivity of the antibody kits were calculated according to the following formulas:

Specificity (%) = 100 × [True negative / (True Negative + False Positive)];

Sensitivity (%) = 100 × [True Positive / (True Positive + False Negative)];

Overall agreement (%) = (True negative + True Positive) / Total tests.

In order to analyze the correlation of serum antibody levels and age with disease severity, we first used the Kruskal Wallis test²⁶ to test if there is any significant difference of IgA among the three groups (Mild, Moderate, Severe). Then Dunn’s test²⁷ was used to perform a pair-wise test between each group, and Benjamini-Hochberg procedure²⁸ was used to adjust p-values. All the above analyses use R software version 3.6.1²⁹. A p value less than 0·05 was judged statistically significant.

RBD-based serologic kits is better than NP-based kits for detecting IgA as well as IgM and IgG

The nucleocapsid protein (NP) is the most abundant protein in coronaviruses, which was reported to be highly immunogenic and often used as a diagnostic marker for coronaviruses such as SARS-CoV³¹. The RBD of the spike protein on viral surface is the ligand binding to the major host receptor ACE2; therefore RBD could be a main target for neutralization antibodies.^{32, 33} In this study, we explored the possibility of using either NP or RBD as an immobilized antigen in for developing a clinical COVID-19 diagnostic kit. Our data (supplementary figure 2) showed RBD-based diagnostic kits were better performed than that of NP in detecting all the three types of antibodies. A few previous studies reported that RBD-based IgM and IgG detection is better than NP once a comparison was made^{19, 23}, and the measurement is agreeable with the titers measured by virus neutralization assays^{23, 24}. We provided here the evidence that RBD as an immobilized antigen is also better than NP in detection serum IgA from COVID-19 patients. The exact mechanisms of difference between the use of two types of viral antigens remain to be resolved. It could be that the NP as a highly basic protein interacts with acidic residues in complementarity determining region in antibodies is less specific. It could also be due to the fact that the NP antigen is expressed in bacteria as most investigators do, and the RBD protein we used is expressed in a human cell line enabling critical glycosylation and high-affinity binding to antibodies raised in COVID-19 patients. Nonetheless, we showed that our serological kits based on SARS-CoV-2 spike protein RBD as an immobilized antigen provide a high sensitivity and specificity for detecting IgA, IgM, and IgG in a quantitative manner.

Our serological kits have overall good performance

Our kits have much higher accuracy than RT-qPCR (sensitivity less than 70%) for detecting viral RNA^9-13, and published immune-assays such as “flow immunoassay” and ELISA in earlier studies^{10-12, 17-21, 23, 24}. When we combined RBD-specific IgA and IgG kits together, the sensitivity, specificity and overall agreement elevate to 99·1%, 100%, and 99·7%, respectively (table 1). In addition, this RBD-based detection kit may also help to screen and detect neutralization antibodies targeting SARS-CoV-2 RBD, because this peptide domain is exposed on viral surface and functions as a ligand binding to the host cell surface receptor ACE2.

Detection of three isotypes of SARS-CoV-2 induced antibodies

Although one serum collected at the 4th day after illness onset was diagnosed as positive by our IgM kit (not IgA or IgG kits in this study), the IgM kit overall showed a lower diagnostic specificity of 92·3% compared to that of IgG and IgA (figure 1). IgM is known to have relatively lower affinity toward antigens compared with that of IgG or IgA. In addition, IgM often causes false positive signals as we also observed (supplemental table 2), due to its pentameric structure³⁴. To the contrary, IgA or IgG antibody does not have this problem. Our RBD-specific IgG kit showed high specificity of 99·8% (figure 1) but relatively low sensitivity of 96·8%. This is expected, because that most (6/7) false negative cases were samples collected at 4-10 days after illness onset when IgG production is likely very low.

Our RBD-based IgA kit showed high sensitivity and specificity of 98·6% and 98·1%, except two sera collected at the 4th day after illness onset. All other sera (2 at the 6th day, 3 at the 7th day, 1 at the 8th day, 6 at the 9th day, and 3 at 10th day after illness onset) were diagnosed as positive. Based on our results, IgA and IgM are produced nearly simultaneously in early stage of infection, while IgA test has less false positives. As a result, IgA should be included in a serological test, which may provide higher diagnostic accuracy for COVID-19. Therefore, we highly recommend the use of RBD-specific IgA/IgG or IgA/IgM/IgG combinational serological test supplementing nucleic acid detection to provide a more accurate diagnosis of COVID-19.

Kinetics of antibody production during COVID-19

We also provide a data set of absolute antibody levels and their production kinetics for all three isotypes of antibodies in serum. Our results revealed that both IgM and IgA have early responses (peaked around 20th day after illness onset), while IgG showed up later (peaked around 25th day after the onset). Rapid increase of the three isotypes of serum RBD-specific antibodies started at about 10 days after illness onset (supplementary figure 4A-C), which is consistent with other reports describing the trends of IgM and IgG levels in serum^14-19. The early appearance of IgA in COVID-19 patients’ sera is probably due to the initial infection of this virus at the respiratory system, which is rich of mucosal immune cells. Due to the low basal level of IgA in serum, it makes SARS-CoV-2 specific IgA detection highly sensitive at early stage of infection. When we analyzed IgA, IgM, or IgG concentrations in the patients’ serum with different COVID-19 severity, we observed that disease severity is positively correlated with IgA antibody concentrations (figure 3A). The underlying mechanisms of this novel observation need to be further investigated in the future.

Clinical implications of high-levels of virus-induced IgA in COVID-19

We observed the presence of high-level of RBD-specific IgA in COVID-19 patients’ sera. It is widely believed that mucosal plasma cells are a major production source of IgA, which is rapidly transported across adjacent epithelial barriers into external secretions. In normal situations, very little IgA enters the blood³⁵. During infection, high-level of pathogen specific IgA has been reported in mucosal for EV-71², influenza³⁶, and SARS³⁷, suggesting the importance of IgA in immune responses to viral infection. It has also been reported that IgA is present in serum of COVID-19 patients, although a small number of patients was involved and study on IgA detection was so far limited^{12, 23, 24}.

IgA is traditionally recognized to play an anti-inflammatory role and prevent tissue damage at mucosal sites. However, recent reports also demonstrated that serum IgA is involved in the formation of immune complexes to amplify inflammatory responses.³⁸ Serum IgA induced proinflammatory cytokine production by macrophages, monocytes and Kupffer cells in non-mucosal tissues including liver, skin and peripheral blood.³⁹ In this study, we observed that IgA was present in COVID-19 patients’ serum, and its levels positively correlated with COVID-19 severity (figure 3A). In our cohort, we also observed that IgG levels were associated with worse clinical outcomes (figure 3C), as previously described^{10, 21}. The latter phenomena has been suggestive of possible antibody-dependent enhancement (ADE) of infection. The immunopathological effects of ADE have been observed in various viral infections, characterized as antibody-mediated enhancement of viral entry and induction of a severe inflammatory response.⁴⁰ It is unclear currently if IgA as well as IgG contributed directly (e.g. via ADE) or indirectly (e.g. leading to a pathogenic inflammatory storm⁴¹) to the worse clinical outcome in severe COVID-19 patients. If a high-level of IgA indeed contributes to aggravations in COVID-19 severe patients, blocking of IgA-Fc alpha Receptor I (FcαRI, CD89, an IgA receptor) interaction could mitigate ADE or inflammatory storms, thus providing a novel treatment strategy.

While the exact origin of serum IgA after SARS-CoV-2 infection remains to be determined, we suspect that lung and gut are probable places of producing large-quantity of IgA by abundant mucosal immune cells at these sites. Interestingly, several reports are available on the detection of viral RNA in stool or anal swabs^{42, 43}. In fact, abdomen abnormality/diarrhea is often complained from COVID-19 patients.⁴³ These observations suggest that gut may be an important place for anti-viral response to coronaviruses, and large amounts of secretory IgA could be detected in these mucosal tissues in addition to that in blood.

Weakness of this study

The current study at the present form has several limitations. We used 216 serum samples from 87 confirmed COVID-19 patients in this study, and serum samples were not available every day for each patient. The earliest collected serum is at the 4th day after self-reported illness onset, and the last one was collected at the 41th day after illness onset. There are only 17 cases of serum samples collected within the first 10 days after illness onset; consequently the accuracy of early diagnosis requires further verification using larger and controlled samples. Similarly, there were only 23 cases of serum samples taken after 30 days post illness onset, hampering an analysis of long-term antibody levels in recovered patients. Most patients enrolled in this study were with clinically moderate symptoms (56/87, 64·4%). There were 17 severe and five critical cases, respectively, accounting for 19·5% and 5·75% respectively. There were also few cases of COVID-19 patients whose symptoms remained mild and serum samples were collected during hospitalization. Therefore, this study of the correlation between antibody levels and disease severity needs further verification.

In summary, this study reports a novel sensitive and quantitative serological testing kit of detecting IgA as well as IgM and IgG, for the diagnostics of COVID-19. Due to its high specificity and sensitivity, this kit could sensitively and quantitatively measure levels of IgA in blood and other tissues. The serological study also provides valuable information for monitoring and understanding of COVID-19.